BlossomHill Therapeutics
A small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor investor investor | €0.0 | round | |
* | $100m | Series B | |
| Total Funding | 000k | ||
Related Content
BlossomHill Therapeutics, Inc. is a biotechnology company specializing in the discovery and development of small molecule drugs. The company focuses on addressing unmet medical needs in the fields of oncology (cancer treatment) and autoimmune disorders (conditions where the immune system attacks the body). Headquartered in San Diego, California, BlossomHill Therapeutics leverages the extensive experience of its founders, Dr. Cui and Dr. Li, who previously founded Turning Point Therapeutics, a company acquired by Bristol Myers Squibb for $4.1 billion in 2022.
BlossomHill Therapeutics operates in the highly specialized and competitive biopharmaceutical market. Its primary clients include healthcare providers, hospitals, and research institutions that require advanced treatments for cancer and autoimmune diseases. The company’s business model revolves around the research and development (R&D) of novel drugs, which involves discovering new compounds, conducting clinical trials, and obtaining regulatory approvals from agencies like the FDA (Food and Drug Administration).
The company generates revenue through multiple channels. Initially, it invests heavily in R&D to create promising drug candidates. Once these drugs show potential, they enter clinical trials. If successful, the drugs receive FDA approval, allowing BlossomHill Therapeutics to market and sell them. Additionally, the company may enter into licensing agreements or partnerships with larger pharmaceutical firms, providing another revenue stream.
BlossomHill Therapeutics has already achieved significant milestones. For instance, its drug Repotrectinib received multiple FDA designations, including Breakthrough Therapy and Fast Track, and was approved for treating locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). Other drugs, such as Elzovantinib and TPX 0046, are in various stages of clinical trials, showcasing the company’s robust pipeline.
Keywords: oncology, autoimmune disorders, drug discovery, small molecule, FDA approval, clinical trials, biopharmaceutical, R&D, San Diego, partnerships.